Doxepin cream relieves eczema-associated pruritus within 15 minutes and is not accompanied by a risk of rebound upon discontinuation

被引:11
作者
Breneman, DL
Dunlap, FE
Monroe, EW
Schupbach, CW
Shmunes, E
Phillips, SB
机构
[1] UNIV CHICAGO HOSP,SECT DERMATOL MC5067,CHICAGO,IL 60637
[2] UNIV DERMATOL CONSULTANTS INC,CINCINNATI,OH
[3] ARGUS RES INC,TUCSON,AZ
[4] MILWAUKEE MED CLIN,MILWAUKEE,WI
[5] MECKLENBURG CLIN RES INC,CHARLOTTE,NC
[6] COLUMBIA SKIN CLIN,COLUMBIA,SC
关键词
doxepin; therapy; clinical investigation; eczema; atopic dermatitis;
D O I
10.3109/09546639709160512
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Doxepin hydrochloride 5% cream has been previously demonstrated to be effective for relief of pruritus associated with atopic dermatitis and simplex chronicus. In these studies, no evaluations prior to 12 h after the first application, or following discontinuation of topical doxepin therapy, were performed. The current study was done to investigate the onset of action of topical 5% doxepin cream and to ascertain whether discontinuance of doxepin therapy is associated with 'rebound' worsening of pruritus. A total of 120 patients with atopic dermatitis or lichen simplex chronicus with moderate to severe pruritus were treated with 5% doxepin cream in a single-blind treatment period (days 0 to 7) followed by a double-blind treatment period (days 7 to 14) in which patients were randomized to receive either doxepin or vehicle cream to evaluate the effects of cessation of active therapy. Pruritus evaluations performed 15 min following application of doxepin cream demonstrated significant antipruritic activity compared with baseline as measured by visual analogue scales of pruritus severity (P<0.001) and pruritus relief (P<0.001). Of the 120 patients, 75% reported reductions in pruritus severity in just 15 min and 84% reported such reductions by 120 min following doxepin cream application. Decreasing pruritus severity and increasing pruritus relief continued significantly through day 7. A statistically significant (P<0.001) improvement in both the pruritus severity rating and the physician's global evaluation of pruritus relief was present on day 7 and continued to day 14 compared with baseline in both treatment groups. Eczema severity was significantly improved on both days 7 and 14 in all treatment groups compared with baseline (P<0.001), with significant continued improvement in the doxepin group on day 14 compared with day 7 (P=0.011). Adverse experiences were predominantly mild to moderate in severity and decreased throughout the study. Within 15 min of application, topically applied 5% doxepin cream provided significant antipruritic activity in patients with atopic dermatitis and lichen simplex chronicus. After completing a 7-day treatment period, it was possible to replace active treatment with an emollient without a rebound effect being observed.
引用
收藏
页码:161 / 168
页数:8
相关论文
共 31 条
[1]  
[Anonymous], ACTA DERM VENERE S92, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]
[2]   HISTAMINE, ANTIHISTAMINES AND ATOPIC ECZEMA [J].
BEHRENDT, H ;
RING, J .
CLINICAL AND EXPERIMENTAL ALLERGY, 1990, 20 :25-30
[3]  
BERNHARD JD, 1994, ITCH MECH MANAGEMENT, P97
[4]   INHIBITION OF HISTAMINE-INDUCED PRURITUS BY TOPICAL TRICYCLIC ANTI-DEPRESSANTS [J].
BERNSTEIN, JE ;
WHITNEY, DH ;
SOLTANI, K .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1981, 5 (05) :582-585
[5]  
BERNSTEIN JE, 1986, J INVEST DERMATOL, V86, P463
[6]   FAILURE OF TERFENADINE IN RELIEVING THE PRURITUS OF ATOPIC-DERMATITIS [J].
BERTHJONES, J ;
GRAHAMBROWN, RAC .
BRITISH JOURNAL OF DERMATOLOGY, 1989, 121 (05) :635-637
[7]   RELIEF OF PRURITUS IN PATIENTS WITH ATOPIC-DERMATITIS AFTER TREATMENT WITH TOPICAL DOXEPIN CREAM [J].
DRAKE, LA ;
FALLON, JD ;
SOBER, A ;
BRENEMAN, DL ;
BROWN, RH ;
CHALKER, D ;
EDWARDS, L ;
FUNICELLA, T ;
GREENE, SL ;
KANTOR, I ;
KATZ, HI ;
MAIZE, JC ;
MILLIKAN, LE ;
MONROE, EW ;
RAIMER, SS ;
SCHUPBACH, CW ;
SMITH, EB .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 31 (04) :613-616
[8]   THE ANTIPRURITIC EFFECT OF 5-PERCENT DOXEPIN CREAM IN PATIENTS WITH ECZEMATOUS DERMATITIS [J].
DRAKE, LA ;
MILLIKAN, LE ;
BRENEMAN, DL ;
CHALKER, D ;
EDWARDS, L ;
FALLON, JD ;
FUNICELLA, T ;
GREENE, SL ;
KANTOR, I ;
KATZ, HI ;
MAIZE, JC ;
MONROE, EW ;
RAIMER, SS ;
SMITH, EB ;
SCHUPBACH, CW ;
SOBER, A .
ARCHIVES OF DERMATOLOGY, 1995, 131 (12) :1403-1408
[9]   MECHANISM OF ACTION OF DOXEPIN IN THE TREATMENT OF CHRONIC URTICARIA [J].
FIGUEIREDO, A ;
RIBEIRO, CAF ;
GONCALO, M ;
ALMEIDA, L ;
POIARESBAPTISTA, A ;
TEIXEIRA, F .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1990, 4 (02) :147-158
[10]  
Fleiss J., 1986, Reliability of measurement: the design and analysis of clinical experiments